Yale University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).

1,492 total trials 254 currently recruiting 1005 completed early-phase tilt top decile by trial count

Yale University: 1,492 sponsored US clinical trials, 254 recruiting.

Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.

Top-decile sponsor footprint

Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 60/100

1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,492 total, page 10 of 30

TERMINATED Phase 2

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

NCT04955743

COMPLETED Phase 1

In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans

NCT04920539

COMPLETED NA

Feasibility of Elder Mistreatment VOICES-CI Screening Tool

NCT05216081

COMPLETED NA

Transgender Health: an Educational RCT

NCT05080335

COMPLETED NA

A Digital Intervention for HIV Prevention in Black Adolescent Girls

NCT04108988

TERMINATED Phase 4

TAP Block Using Liposomal Bupivacaine for Post-cesarean Delivery Analgesia- Walking Towards Recovery

NCT04393207

COMPLETED

The In4M Study: Integrating 4 Methods to Assess Physical Function in Cancer Patients

NCT05214144

TERMINATED Phase 2

Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

NCT04613453

COMPLETED Phase 4

MoviPrep® Versus GoLYTELY® Bowel Preparation in Hospitalized Patients Undergoing Colonoscopy

NCT05054036

COMPLETED NA

Virtual Physical Activity for Type 1 Diabetes

NCT05163912

COMPLETED NA

Prescription Digital Therapeutic for the Treatment of Insomnia

NCT04909229

COMPLETED Phase 1

Feasibility of VOICES Elder Abuse Intervention in Primary Care Setting (VOICES-PC Feasibility)

NCT05224843

COMPLETED NA

Feasibility and Efficacy of a Digital Neurotherapy Protocol for Management of Depression, Cognition, and Quality of Life in Cancer Survivors

NCT04961047

COMPLETED Early Phase 1

Safety and Tolerability of Cannabidiol Among Persons With Opioid Use Disorder Receiving Methadone or Buprenorphine

NCT05076370

COMPLETED NA

The Infant- Toddler Climate of Healthy Interactions for Learning and Development (I-T CHILD)

NCT05132374

COMPLETED Phase 2

Ketamine for the Treatment of Depression in Parkinson's Disease

NCT04944017

COMPLETED NA

Sympathetic Activation in Obesity

NCT04946552

COMPLETED NA

Pragmatic Trial Of Alerts for Use of Mineralocorticoid Receptor Antagonists

NCT04903717

COMPLETED NA

Stimulation of the Thalamus for Arousal Restoral in Temporal Lobe Epilepsy

NCT04897776

COMPLETED NA

Personalized Recommendations for Acute Kidney Injury (AKI) Care

NCT04040296

COMPLETED NA

Single-Session Intervention Targeting Emotional Awareness, Clarity, and Acceptance to Reduce Depression/Anxiety

NCT05109507

COMPLETED NA

Digital Interventions to Treat Hazardous Drinking

NCT04890652

COMPLETED NA

Preliminary Test of Reactive Carrot Incentives in a Practice Quit Environment With Contingency Management Incentives

NCT05072301

COMPLETED NA

Implementing Fit Kit Colorectal Cancer (CRC) Screening in High Risk Populations

NCT04848051

COMPLETED Phase 3

Lidocaine Patches After Cesarean Section

NCT04443569

TERMINATED Phase 2

Digoxin In Treatment of Alcohol Associated Hepatitis

NCT05014087

COMPLETED NA

LGBTQ-affirmative CBT for Youth

NCT05408858

COMPLETED

The Adapting Disease Specific Outcome Measures Pilot Trial for Telehealth in Myasthenia Gravis

NCT05917184

COMPLETED NA

Heart Watch Study: a Pragmatic Randomized Controlled Trial

NCT04468321

COMPLETED NA

Feedback and Outcomes for Clinically Useful Student Services (FOCUSS)

NCT05039671

COMPLETED Phase 1

Repeat Dosing of Psilocybin in Migraine Headache

NCT04218539

COMPLETED Phase 2

Weight Regain Treatment Post-Bariatric Surgery

NCT04662801

COMPLETED NA

Metabolic Changes Induced by a Very Low Carbohydrate Diet in Youth With Type 1 Diabetes

NCT04955691

COMPLETED Early Phase 1

Examine the Feasibility of a Standardized Field Test for Marijuana and Alcohol Impairment: Laboratory Evaluations

NCT04856566

COMPLETED NA

Reducing Depression-related Stigma and Increasing-treatment Seeking Among Black Adolescents

NCT04890990

COMPLETED NA

PRagmatic Trial Of Messaging to Providers About Treatment of Heart Failure in the Inpatient Setting

NCT04686604

COMPLETED NA

Outcomes After Albumin Vs Lactated Ringer's Solution in CABG and AVR Procedures

NCT04652375

COMPLETED NA

Optimal Duration of Post-Operative Activity Restriction After Midurethral Sling Procedures

NCT04817839

COMPLETED NA

Assessment, Feedback, Incentive, Exchange (AFIX OB) A Customizable Quality Improvement Intervention to Increase Maternal Vaccine Uptake

NCT04678271

TERMINATED NA

Neurofeedback in Individuals With Substance Use Disorders

NCT04188288

COMPLETED Early Phase 1

Nicotine's Potential Abuse With Menthol

NCT04535362

COMPLETED NA

Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID)

NCT04394715

COMPLETED Phase 4

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

NCT04649229

COMPLETED NA

Infrared Wraps Effect on Oxygenation of Diabetics Arm, Feet and Lower Leg

NCT04460612

COMPLETED NA

Take 5 + Audio Clip Randomized Control Trial

NCT04608877

COMPLETED NA

Changes in Fitness and Strength in Postoperative Cardiac Patients Undergoing Exercise Therapy: Biological and Functional Mechanisms of Recovery

NCT04903691

COMPLETED Early Phase 1

Neuroimaging Mechanisms by Which Memory and Glucocorticoids Promote Risky Drinking

NCT04896489

COMPLETED

Yale COVID-19 Recovery Study

NCT04895189

COMPLETED NA

Switching to Potential Reduced Exposure Products in Adult Smokers

NCT04250727

COMPLETED Phase 1

M1 Schizophrenia PET Study

NCT05105542

← Previous Page 10 of 30 Next →

Phase Distribution

PhaseTrial count
Phase 1 312
Phase 2 267
Phase 3 52
Phase 4 47

What is open in the Yale University pipeline

254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).

Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).

Top condition: Opioid Use Disorder (19 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Yale University: open-pipeline peers nationwide

Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Yale UniversityWashington University School of MedicineJohns Hopkins UniversityUniversity of PennsylvaniaNovartis PharmaceuticalsNYU Langone HealthCSL BehringPenn State UniversityUniversity of Hawaii
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,492 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this Yale University page

1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.

  • 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.